Emerald Advisers LLC cut its holdings in Livent Corporation (NASDAQ:LTHM) by 97.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,089 shares of the company’s stock after selling 846,299 shares during the period. Emerald Advisers LLC’s holdings in Livent were worth $132,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in LTHM. Northern Trust Corp acquired a new stake in shares of Livent during the 4th quarter worth $4,423,000. Geode Capital Management LLC purchased a new stake in Livent during the 4th quarter worth $3,737,000. Bank of America Corp DE purchased a new stake in Livent during the 4th quarter worth $305,000. MetLife Investment Advisors LLC purchased a new stake in Livent during the 4th quarter worth $229,000. Finally, Metropolitan Life Insurance Co. NY purchased a new stake in Livent during the 4th quarter worth $167,000.
NASDAQ:LTHM opened at $6.18 on Thursday. The firm has a 50-day moving average price of $6.84. Livent Corporation has a 1-year low of $5.49 and a 1-year high of $19.90.
Livent (NASDAQ:LTHM) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.12 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.12. The firm had revenue of $114.00 million during the quarter, compared to analysts’ expectations of $108.85 million. Livent’s quarterly revenue was up 5.7% on a year-over-year basis.
A number of analysts recently weighed in on LTHM shares. Vertical Research cut shares of Livent from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th. Nomura set a $9.00 price target on shares of Livent and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Zacks Investment Research cut shares of Livent from a “hold” rating to a “sell” rating in a research report on Thursday. Credit Suisse Group reaffirmed an “outperform” rating and set a $12.00 price target (down from $18.00) on shares of Livent in a research report on Thursday, May 9th. Finally, Gabelli cut shares of Livent from a “buy” rating to a “sell” rating in a research report on Thursday, May 9th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the stock. Livent currently has a consensus rating of “Hold” and a consensus target price of $15.11.
Livent Corporation manufactures and sells performance lithium compounds that are used primarily in energy storage, specialty polymers, and chemical synthesis application. The company offers lithium compounds for use in applications that have specific performance requirements, including battery-grade lithium hydroxide for use in high performance lithium-ion batteries; and supplies butyllithium, which is used as a synthesizer in the production of polymers and pharmaceutical products, as well as a range of specialty lithium compounds, including high purity lithium metal, which is used in the production of lightweight materials for aerospace applications and non-rechargeable batteries.
Recommended Story: Beige Book
Want to see what other hedge funds are holding LTHM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Livent Corporation (NASDAQ:LTHM).
Receive News & Ratings for Livent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livent and related companies with MarketBeat.com's FREE daily email newsletter.